Research Article
CCL27: Novel Cytokine with Potential Role in Pathogenesis of Multiple Sclerosis
Table 3
MS serum cytokines differ from healthy controls.
| Analyte | Secondary RRMS acute (ng/mL) | RRMS remission (ng/mL) | MS onset (ng/mL) | Control (ng/mL) |
| IL-2Ra | 376.1 ± 71.7 | 301.5 ± 61.2 | 481.0 ± 303.5 | 36.3 ± 4.1 | = 0.001 | < 0.04 | | | IL-12p40 | 3892.5 ± 821.9 | 3248.8 ± 327.7 | 4016.3 ± 571.7 | 86.0 ± 6.1 | = 0.003 | = 0.00014 | = 0.00008 | | IL-16 | 51.0 ± 10.8 | 123.6 ± 51.7 | 42.0 ± 13.1 | 241.1 ± 67.9 | = 0.01 | | | | IL17A | 119.0 ± 12.0 | 104.3 ± 8.9 | 82.7 ± 28.0 | 44.7 ± 6.3 | < 0.0003 | = 0.0023 | | | IL22 | 216.9 ± 15.0 | 162.6 ± 9.4 | 173.1 ± 28.8 | 149.4 ± 18.7 | < 0.02 | | | | = 0.007 | | | | IL23 | 530.2 ± 84.5 | 527.3 ± 27.2 | 585.3 ± 180.9 | 62.2 ± 8.9 | < 0.0004 | = 0.000000002 | = 0.003 | | CCL2 | 821.1 ± 80.5 | 918.3 ± 54.8 | 1152.5 ± 192.5 | 145.6 ± 23.0 | < 0.00002 | = 0.00000001 | < 0.005 | | CCL3 | 72.3 ± 18.2 | 73.1 ± 10.7 | 89.4 ± 10.8 | 35.7 ± 4.1 | | | = 0.0002 | | CCL7 | 317.0 ± 65.4 | 286.7 ± 63.6 | 211.2 ± 93.5 | 119.8 ± 6.3 | = 0.03 | | | | CCL27 | 4192.9 ± 773.6 | 4282.5 ± 912.8 | 3152.7 ± 582.9 | 854.6 ± 51.0 | < 0.005 | | < 0.002 | | CXCL1 | 362.7 ± 64.1 | 332.0 ± 48.7 | 379.9 ± 194.6 | 135.6 ± 40.6 | = 0.02 | | | | CXCL9 | 2319.4 ± 687.2 | 1878.1 ± 314.4 | 967.2 ± 536.4 | 2461.8 ± 301.6 | | | = 0.04 | | M-CSF | 438.7 ± 75.4 | 401.1 ± 43.3 | 495.6 ± 142.0 | 37.3 ± 7.0 | = 0.001 | = 0.00065 | < 0.005 | | MIF | 368.3 ± 53.2 | 462.2 ± 43.2 | 173.5 ± 15.8 | 148.6 ± 38.9 | = 0.01 | < 0.003 | | | CXCL12 | 4089.7 ± 1952.1 | 2174.5 ± 188.5 | 1254.8 ± 22.6 | 2582.4 ± 166.5 | | | < 0.001 | | TRAIL | 283.1 ± 22.7 | 271.1 ± 72.0 | 332.5 ± 29.2 | 46.2 ± 1.5 | = 0.000002 | | = 0.000006 | |
|
|